Delving into the Latest Updates on Chengdu Genevector Biotechnology Co. Ltd. with Synapse

Overview

Tags

Congenital Disorders

Other Diseases

Eye Diseases

AAV based gene therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

AAV based gene therapy	6

Top 5 Target	Count

VEGF(Vascular endothelial growth factor)	1
factor IX(Coagulation factor IX)	1
ABCA4(ATP binding cassette subfamily A member 4)	1
XLRS1(Retinoschisin)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 1 Clinical

Phase 2 Clinical

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

JWK-006 ( ABCA4 )	Stargardt Disease More	Phase 2 Clinical
JWK-001 ( VEGF )	Wet age-related macular degeneration More	Phase 2 Clinical
JWK007	Muscular Dystrophy, Duchenne More	Phase 1
JWK-002 ( XLRS1 )	Retinoschisis More	Preclinical
JWK004 ( factor IX )	Hemophilia B More	Preclinical